Toppoint Holdings Inc. Announces Closing of $10 Million Initial Public Offering

(NYSE MKT:TOPP), NORTH WALES, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) — Toppoint Holdings Inc. (“Toppoint” or the “Company”) today announced the closing of its previously announced initial public offering of an aggregate of 2,500,000 shares of its common stock (the “Shares”) at an offering price of $4.00 per share to the public, for a total […]

CienOne Highlights Cost-Effective Ground Transport as an Alternative to Air Medical Services

Fort Worth, TX – CienOne, a leader in non-emergency long-distance medical transportation, is proud to emphasize the significant cost savings and quality care offered by long distance ground medical transport as a viable alternative to air transport. With rising healthcare costs impacting families nationwide, CienOne is helping patients and their loved ones access exceptional care

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rentokil

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rentokil To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Rentokil between December 1, 2023 and September 10, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh

AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, today announced a C$820 million (US$570m) investment in Canada, creating more than 700 high-skilled jobs, across all areas of the business.

CANADIANS REJECT TRUMP’S TARIFF THREATS: NEW CLC POLL

A new poll commissioned by the Canadian Labour Congress (CLC) revealsCanadians are seriously concerned with the economic and political risks posed by U.S. President Donald Trump. Polling of 1500 eligible voters, conducted between January 13 and 20, 2025 by GQR Canada, reveals that a majority of Canadians believe that Trump's threats of a 25% tariff

Vadara Quartz Announces International Expansion into the United Kingdom

Vadara Quartz Surfaces, a leading manufacturer of artisan handcrafted quartz surfaces, has begun an international expansion into the United Kingdom. https://mma.prnewswire.com/media/2604834/Vadara_ScandiBlue.jpg After years of establishing a track record in the United States, Vadara has set sights on expanding into key international markets by capitalizing on its innovative designs, streamlined operations, and keen insight into local

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Crocs, Inc. (CROX) Shareholders

NEW YORK, NY / ACCESS Newswire / January 23, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=124697&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Opportunity Finance Network Appoints New Leadership as Chair and Vice Chair for its Board of Directors

Opportunity Finance Network (OFN), the nation's leading investment intermediary and network of community development financial institutions (CDFIs) announced that Aisha Benson, President and CEO of Nonprofit Finance Fund (NFF), and Henry Jiménez, President and CEO of Propel Nonprofits, were elected to serve, respectively, as Chair and Vice-Chair of the OFN Board of Directors. https://mma.prnewswire.com/media/2346407/OFN_Logo_Logo.jpg “Aisha

EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025

No dose-limiting toxicities, severe adverse events, or on-target off-tumor toxicities across all dose cohorts Deep and durable response observed in gastroesophageal cancer EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR™platform and SCL mRNA technology EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene immunotherapies

Scroll to Top